Connect OpenTG to ChatGPT or Claude in 60 seconds

Try it

더바이오 11월 20일 주요뉴스 https://www.

더바이오 뉴스룸
6,553 subscribers
Open in Telegram
더바이오 11월 20일 주요뉴스

https://www.thebionews.net/edit/webzine.html?idxno=688

● GLP-1 다음은?…글로벌 빅파마 ‘아밀린’ 기반 비만약 경쟁, 국내 기업도 가세
https://www.thebionews.net/news/articleView.html?idxno=30480

● 키트루다SC, 독일 판매금지 가처분 뒤집혔다…"현지 출시 길 열려"
https://www.thebionews.net/news/articleView.html?idxno=30479

● [단독]제넨텍과 기술이전 '브리즈바이오', 코스닥 상장예심 청구
https://www.thebionews.net/news/articleView.html?idxno=30478

● 셀트리온 “항체 중심 신약 개발서 신규 모달리티로 확장…글로벌 협력 강화”
https://www.thebionews.net/news/articleView.html?idxno=30476

● [컨콜] 노바티스, 종근당서 도입 ‘CKD-510’ 부정맥 신약 파이프라인 재확인
https://www.thebionews.net/news/articleView.html?idxno=30508

● 바이오헤이븐, 에임드바이오서 도입한 ‘FGFR3 ADC’ 임상1상서 ORR 60%
https://www.thebionews.net/news/articleView.html?idxno=30481

● 아델, 수요 예측 부진에 코스닥 시장 상장 ‘철회’…재도전 시점 ‘미정’
https://www.thebionews.net/news/articleView.html?idxno=30499

● 사노피, ‘인필브레이’ 3형 고셔병 신경증상 치료제로 FDA 승인…‘세계 최초’
https://www.thebionews.net/news/articleView.html?idxno=30471

● 美 레볼루션, ‘라손큐’ 전이성 췌장암 1차 치료 확대 청신호…반응률 60.7%
https://www.thebionews.net/news/articleView.html?idxno=30502

● GC녹십자, 차세대 RNA·LNP 기술로 ‘인비보 CAR-T·암백신’ 개발 확장
https://www.thebionews.net/news/articleView.html?idxno=30500

● 오스코텍, 서스틴베스트 ESG 평가 ‘A등급’…“두 단계 상승”
https://www.thebionews.net/news/articleView.html?idxno=30493

● 대웅제약 ‘펙수클루’, 내시경 후 위궤양 완치율 90.2%…PPI 제제比 15%p↑
https://www.thebionews.net/news/articleView.html?idxno=30491

● 美 의회 자문위, 中 바이오 지배력 확대 경고…“신약개발 의존 심화”
https://www.thebionews.net/news/articleView.html?idxno=30487

● HLB펩, 스킨메드 ‘아리포타이드’ 임상2상용 원료의약품 CDMO 계약 체결
https://www.thebionews.net/news/articleView.html?idxno=30516

● 엘앤씨바이오, 페루서 ‘리투오’ 공식 론칭…중남미 공략 본격화
https://www.thebionews.net/news/articleView.html?idxno=30505

● 고려대 안암병원 김병수 교수, ‘제40회 약의 날’ 식약처장 표창 수상
https://www.thebionews.net/news/articleView.html?idxno=30503

● 라메디텍, 독일 ‘메디카’서 레이저 채혈기 유럽 진출 협력 논의
https://www.thebionews.net/news/articleView.html?idxno=30492

● 큐라클, 경구용 망막질환 치료 후보물질 ‘CU06’ 美 임상2b상 IND 신청
https://www.thebionews.net/news/articleView.html?idxno=30498

● 케이메디허브, ‘메디카 2026’서 국내기업 7곳 유럽진출 지원
https://www.thebionews.net/news/articleView.html?idxno=30497

● 팜젠사이언스, 서스틴베스트 ESG 평가 4회 연속 A등급
https://www.thebionews.net/news/articleView.html?idxno=30496

● HLB Pharmaceutical to drive production of global anticancer drugs ‘Lyrfigtu and rivoceranib’ at new Hyangnam plant
https://www.thebionews.net/news/articleView.html?idxno=30517

● LAMEDITECH enters UK and Ireland with 'PURAXEL' skin care device, expanding sales network
https://www.thebionews.net/news/articleView.html?idxno=30515

● Dong-A ST confirms blood uric acid reduction effect of obesity drug candidate ‘DA-1726’ in U.S. Phase 1 clinical trial
https://www.thebionews.net/news/articleView.html?idxno=30514

● G2GBIO registers Australian patent for once-monthly sustained-release formulation of ‘semaglutide’
https://www.thebionews.net/news/articleView.html?idxno=30513

● HLB Therapeutics ‘RGN-259’ misses statistical significance on primary endpoint in U.S. Phase 3 topline results
https://www.thebionews.net/news/articleView.html?idxno=30512

● Alteogen's new obesity drug candidate posts half-life four times longer than Eli Lilly's 'retatrutide' in animal studies
https://www.thebionews.net/news/articleView.html?idxno=30511

● Samsung Medical Center hits 109 cases of ‘ROSA’ robotic epilepsy surgery, a record high in Korea
https://www.thebionews.net/news/articleView.html?idxno=30510

● MSD Korea holds event marking 10th anniversary of Keytruda’s domestic approval for lung cancer
https://www.thebionews.net/news/articleView.html?idxno=30509

● Vaxdigm Selected for KRW 800 Million Ministry of Health and Welfare R&D Project to Build Generative AI-Based Vaccine Design Platform
https://www.thebionews.net/news/articleView.html?idxno=30483

● “30,000 depression patients unresponsive to existing medications gain new treatment opportunity with ‘Spravato’ insurance coverage”
https://www.thebionews.net/news/articleView.html?idxno=30477

*제약바이오 11월 20일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
https://www.youtube.com/watch?v=m0IwSXRIzok
Open post in Telegram